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Expression of the transcription factor c-Jun is induced in neurons of
the central nervous system (CNS) in response to injury. Mechanical
transection of the nigrostriatal pathway at the medial forebrain
bundle (MFB) results in the delayed retrograde degeneration of the
dopamine neurons in the substantia nigra pars compacta (SNc) and
induces protracted expression and phosphorylation of c-Jun. How-
ever, the role of c-Jun after axotomy of CNS neurons is unclear. Here,
we show that adenovirus-mediated expression of a dominant neg-
ative form of c-Jun (Ad.c-JunDN) inhibited axotomy-induced dopa-
mine neuron death and attenuated phosphorylation of c-Jun in nigral
neurons. Ad.c-JunDN also delayed the degeneration of dopaminergic
nigral axons in the striatum after MFB axotomy. Taken together,
these findings suggest that activation of c-Jun mediates the loss of
dopamine neurons after axotomy injury.
In the central nervous system (CNS), axon transection proximal tothe neuron soma results in neuronal death and a failure of the
injured axons to regenerate. Whereas the mechanisms regulating
cell death or inhibition of neurite regeneration after axotomy
remain unclear, increasing evidence suggests that these are regu-
lated processes, controlled by multiple, discrete biochemical signals
(1–3). Of the signaling pathways associated with neuronal death, a
role for the stress-activated protein kinasec-Jun N-terminal kinase
(SAPKJNK) signaling pathway has been implicated in nerve
injury (4, 5). In this regard, correlative studies have described
increased expression of c-Jun and JNK activity after axotomy (6–8).
However, the precise role of c-Jun expression in the response of
CNS neurons to axotomy injury is incongruous, because expres-
sionactivation of c-Jun has been correlated with both the regen-
eration of nerve fibers and the mediation of neuronal death (refs.
9–11, and reviewed by Herdegen et al. in ref.12).
Here, we have addressed the role of c-Jun expression after
axotomy injury in the central nervous system by using the medial
forebrain bundle (MFB) axotomy model of dopamine neuron death
in vivo. In this model, mechanical transection of the MFB results in
the protracted loss of dopamine neurons in the substantia nigra pars
compacta (SNc) and the commensurate depletion of dopaminergic
innervation of the striatum (13, 14). This injury model has been well
characterized for both the progress of neuronal death, and the
activationexpression of the c-JunJNK pathway (6, 8, 13, 14).
Accordingly, we engineered an adenovirus expressing a dominant
negative c-Jun (15), and examined the functional consequences of
impairing the c-JunJNK signaling pathway in nigrostriatal dopa-
mine pathway after MFB axotomy. We provide evidence to support
a preeminent role for the c-JunJNK pathway in axotomy-induced
death of dopamine neurons in vivo.
Materials and Methods
Animals. Male Wistar rats (150–175 g; Charles River Breeding
Laboratories) were used for all experiments in this study. All
animals and procedures were approved by the University of Ottawa
Animal Care Committee, and were maintained in strict accordance
with the Guidelines for the Use and Treatment of Animals set out
by the Animal Care Council of Canada.
Intrastriatal Administration of Adenoviruses and Fluorogold. Recom-
binant adenoviral vectors were constructed by using the Cre-lox
system (16). The FLAG-tagged c-Jun dominant negative (c-
JunDN) were generously provided by J. Whitfield and J. Ham (15).
Adenoviruses (3 l; 1  107 particles per l per construct)
containing either c-JunDN (Ad.c-JunDN) or lacZ (Ad.lacZ) were
stereotaxically injected into the right dorsolateral striatum 0.7 mm
rostral to bregma, 2.5 mm to the right of midline, and 5.2 mm
relative to the skull surface, at an infusion rate of 0.5 lmin by
using a syringe pump (PHD2000, Harvard Apparatus; ref. 17).
Injections of the fluorescent retrograde tracer, Fluorogold (FG; 0.2
l of 2.0% in 0.9% saline; Fluorochrome, Engleweed, CO) were
also administered bilaterally into the striata at the same coordinates
as the adenovirus and the equivalent site of the contralateral
hemisphere (18).
Medial Forebrain Bundle Axotomy. Unilateral axotomy of the MFB
was performed one week after intrastriatal adenovirus administra-
tion by using a Scouten wire knife (Kopf Instruments, Tujunga,
CA). The MFB was transected at the level 3.8 mm caudal to
bregma: the knife was moved 2.4 mm to the right of the midline, and
lowered 8.0 mm below the skull surface, and the blade was extended
and raised 2.5 mm, then lowered and retracted, as described
previously (refs. 17 and 19–22; Fig. 1A). Postmortem validation of
the lesion site was determined in every animal by hematoxylin and
eosin staining (Fig. 1B). To examine the effects of c-JunDN
expression on axotomy-induced neuronal death, groups of rats
received intrastriatal injections of either adenoviruses and FG (n
6 per group) or adenovirus alone (n  12 per group), followed by
MFB axotomy 1 week later. Fourteen days after MFB axotomy,
animals were perfused or subjected to HPLC analysis (see below).
Additional groups of animals were used to examine changes in
axotomy-induced gene expression and TH 3 (n 3 per virus) or 7
days (n 3–4 per virus) postaxotomy. A final group of adenovirus-
axotomized rats (n 6 per virus) were killed 50 days postaxotomy
to assess the long-term effects of adenoviral gene expression on
nigral neuron survival.
Immunohistochemistry. Animals were perfused transcardially with
saline (0.9%; 200 ml) followed by an equivalent volume of para-
formaldehyde (4.0% in 0.1 M phosphate buffer). Tissues were
postfixed overnight and then cryoprotected by using 10% sucrose
in 0.1 M phosphate buffer. Serial coronal sections were collected
from the forebrain and midbrain levels of all animals and developed
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for immunohistochemical analysis of protein expression in striatal
and nigral regions, respectively, as described previously (23). Sec-
tions from each subject and treatment group were stained in
parallel by using these antibodies: FLAG (1:500, Chemicon), -
galactosidase (1:1000; Promega), phosphoserine-63 or 73 c-Jun
(both 1:500; Santa Cruz Biotechnology), c-Jun (1:1500: no. 9162,
NEB, Beverly, MA), JunD and cAMP-responsive element binding
protein (CREB; both 1:2000; R. Bravo, Bristol-Myers Squibb,
Princeton, NJ), FosB (1:5000; Santa Cruz Biotechnology), and
tyrosine hydroxylase (TH, 1:10,000; Incstar, Stillwater, MN). Dig-
ital photomicrographs were captured by using a computer-based
image analysis system, and striatal densitometry measurements
(five sections per subject;1.0 mm to0.26mm from bregma) were
made by using a subroutine program (Northern Eclipse, Empix
Imaging, Mississauga, ON, Canada), as described (17).
Assessment of Dopamine Neuron Survival. SNc neuron survival after
MFB axotomy was determined by immunohistochemical detection
of the dopamine phenotype marker, TH, and then confirmed by the
presence of the fluorescent tracer FG. Because of the topographic
nature of the dopaminergic projections from the SNc to the
striatum, retrograde transport of adenoviruses after intrastriatal
administration only labeled a subpopulation of the SNc (ref. 17;
4.8 to5.6 mm caudal from bregma, ref. 24), which included the
medial terminal nucleus (MTN) of the accessory optic tract. Hence,
the MTN was used as an anatomical land mark to ensure that the
same level of the medial SNc was analyzed between hemispheres,
animals, and treatment groups (17, 25, 26). Thus, every fifth section
was collected through the medial SNc (six sections per animal). The
number of nucleated TH- or FG-positive neurons was counted in
both lesioned and contralateral SNc, and the proportion of nigral
neuron survival was expressed as a percentage of the unlesioned
hemisphere (17, 27).
High Performance Liquid Chromatography. Dopamine levels were
determined in the caudate tissue extracts from MFB axotomized
rats (n  6 per group, adenovirus alone) 3 h after administration
of D-amphetamine (2.0 mgkg, s.c.). Briefly, tissues were placed in
0.5 ml homogenizing solution (5 ml methanol with 500 ml water,
which contained 14.17 g monocholoracetic acid and 0.018 g EDTA)
and stored at 80°C until analysis. Striatal concentrations of the
dopamine metabolite 3,4-dihydroxyphenylacetic acid were mea-
sured by using HPLC with electrochemical detection, as described
elsewhere (28, 29).
Statistical Analyses. All data were analyzed by using two-tailed,
unpaired Student t tests (unless stated otherwise). Differences were
considered significant when P  0.05.
Results
Adenoviral Mediated Expression of a Dominant Negative (DN) c-Jun in
Nigral Neurons. We first determined the retrograde transportation
and expression of the c-JunDN-FLAG and lacZ containing adeno-
viruses in the dopamine neurons of the substantia nigra pars
compacta after intrastriatal administration. By using immunoflu-
orescence histochemistry, expression of c-JunDN was detected in
dopamine neurons of the SNc 1 week after intrastriatal adenovirus
injection. FLAG-like immunoreactivity, which detected the tag
epitope added to the c-JunDN (Fig. 2B), revealed that adenoviral-
mediated gene expression was found in neurons colabeled by TH
(Fig. 2D). Similar results were obtained for expression of -galac-
tosidase (Ad.lacZ; data not shown). Adenovirally delivered pro-
teins were not detected in the contralateral hemisphere of either
adenovirus-treated group (Fig. 2 A and E). In the ventral midbrain,
expression of adenoviral delivered proteins was largely exclusive to
dopamine neurons. Expression of c-JunDN in SNc neurons per-
sisted after MFB axotomy and revealed predominantly nuclear
localization of the c-JunDN protein, although some cytoplasmic
staining was also observed (Fig. 2F). However, by 50 days after
MFB axotomy, adenoviral-mediated expression was no longer
detectable in the ipsilateral SNc (Fig. 2H).
c-JunDN Prevents Axotomy-Induced Dopamine Neuron Death. To
determine whether c-JunDN expression could prevent the loss of
nigral dopamine neurons after MFB axotomy, groups of rats were
injected with adenovirus and received axotomy 1 week later (Fig. 3).
Fig. 1. (A) Schematic line drawing of a coronal section from rat brain indicating
the site and extent of mechanical injury made by the Scouten wire knife to
transect the MFB. Verification of anatomical MFB transection was accomplished
by hematoxylin and eosin staining of sections from every animal (3.6 to4.16
mm caudal to bregma; ref. 24), as demonstrated by representative section shown
(B). LinedrawingschematicofcoronalbrainsectionadaptedfromatlasofPaxinos
and Watson (24).
Fig. 2. Intrastriatal adenovirus administration results in retrograde labeling of
dopamine neurons in the SNc. Expression of c-JunDN was detected 1 week later
in the SNc ipsilateral to the adenovirus injection (B), but not in the contralateral
hemisphere (A). Immunohistochemical detection of FLAG (Ad.c-JunDN) was pre-
dominantly in SNc neurons expressing TH (C and D). Fourteen days after MFB
axotomy,FLAGimmunoreactivitywas still detectable inSNcneurons ipsilateral to
injection of Ad.c-JunDN (F), yet by 50 days postinjury, adenovirus expression was
not detectable in the SNc (H). FLAG expression was not detected in the contralat-
eralSNcatthesetimepoints (EandG,respectively). Scalebars160m(A–D)and
40 m (E–H).
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Quantification of TH-positive neurons in the lesioned SNc, when
compared with the unlesioned (contralateral) hemisphere, revealed
that, 3 days postaxotomy, Ad.lacZ-treated animals had 70.67 
5.2% (mean SEM) of nigral neurons, whereas Ad.c-JunDN had
83.09  5.9% survival (P  0.15). However, by 7 days after MFB
axotomy, Ad.lacZ-treated animals exhibited significant neuronal
loss whereas Ad.c-JunDN-treated axotomized rats revealed signif-
icantly more nigral TH neurons (43.95 3.8% vs. 67.76 4.1%,
respectively; P 0.0008). Increased neuronal survival was observed
in Ad.c-JunDN-treated rats 14 days after axotomy (65.52 10.7%),
whereas Ad.lacZ-treated animals exhibited increased loss of TH
nigral neurons at this same time point (34.97  0.6%; P  0.01).
Because axotomy injury may elicit a loss of TH expression rather
than cell death (30), we also assessed SNc neuron survival by using
FG as an independent marker of cell survival. Animals subject to
axotomy and expressing c-JunDN had more FG-labeled SNc neu-
rons (44.49 7.3%) than lacZ-treated controls (19.40 4.7%; P
0.02; Fig. 3H). Although the numbers of FG cells were slightly
lower in both treatment groups than that assessed by TH staining,
this is likely due to the fact that 23% of SNc neurons project to
the contralateral nigra, hence these neurons would not be FG
labeled (14). Taken together, these findings are consistent with the
notion that c-JunDN is neuroprotective in this model of neuronal
injury.
Previous work by others has determined that expression and
activation of c-Jun in nigral neurons is maintained for up to 50 days
after MFB axotomy (8). Because expression of c-JunDN signifi-
cantly reduced axotomy-induced neuronal loss, we also determined
whether protection by c-JunDN depended on sustained expression
adenovirus-mediated protein. Quantitative assessment of SNc neu-
rons survival 50 days after MFB axotomy revealed that the degree
of neuronal loss did not differ between Ad.c-JunDN and Ad.lacZ
treatment groups (36.75  9.38% vs. 31.47  4.37%, respectively)
(Fig. 3G). Hence, neuroprotection in Ad.c-JunDN-treated animals
was lost by 50 days postaxotomy (57 days post adenovirus admin-
istration)—and consistent with the observed loss of adenovirus-
mediated gene expression (Fig. 2).
c-JunDN Attenuates Striatal Dopaminergic Fiber Degeneration After
Axotomy. Mechanical transection of the MFB separates the dopa-
minergic nerve fibers in the striatum from the nigral cell bodies.
Because we had observed protection of nigral neurons, we also
investigated whether expression of c-JunDN effected the loss of the
nigral axons distal to the site of transection. Striatal sections from
Ad.lacZ- and Ad.c-JunDN-treated animals 14 days after axotomy
were assessed for immunohistochemical detection of TH, and the
density of fibrous staining was quantified. In lacZ-treated animals,
axotomy induced a profound depletion of dopaminergic fibers in
the striatum ipsilateral to the MFB transection (Fig. 4B). When
compared with the contralateral hemisphere (Fig. 4A), axotomy
induced an 87% depletion of striatal TH immunoreactive fiber
labeling (Fig. 4E). In contrast, MFB axotomy reduced the density
of fibrous labeling in the ipsilateral striatum of Ad.c-JunDN-treated
rats by only 49.2% (Fig. 4 C and D). The difference in dopaminergic
afferent staining in the striatum of the lesioned sides was signifi-
cantly different (P  0.02), whereas striatal dopaminergic fibrous
Fig. 3. Ad.c-JunDN attenuates loss of nigral dopamine neurons after MFB axotomy. Representative TH immunoreactivity in the SNc from unlesioned (A), and rats
injected with either Ad.lacZ (B), or Ad.c-JunDN (C), 14 days after MFB axotomy. Arrow indicates the medial terminal nucleus (MTN), an anatomical landmark used to
ensure for comparisons between sections (see Materials and Methods). Retrograde labeling of neurons in the SNc after intrastriatal injection of FluoroGold (FG) from
unlesioned(D)Ad.lacZorAd.c-JunDN14daysafterMFBaxotomy(EandF, respectively). (G)QuantificationofTHneurons in theSNcatvaryingtimesafterMFBaxotomy:
Ad.lacZ (white bars), Ad.c-JunDN (black bars) (P 0.0001, ANOVA; *, P 0.001, Newman-Keuls Multiple Comparison test; n 3–4 per group, days 0–7, 50, n 6 day
14). (H) Quantification of FG-labeled neurons in the SNc confirmed increased survival of SNc neurons after MFB axotomy in Ad.c-JunDN-treated rats, when compared
with lesioned Ad.lacZ-treated animals (n 6 per group; *, P 0.02 t test). Scale bar in C 350 m (A-C) and 100 m in F (D–F).









labeling in the contralateral hemisphere of both treatment groups
did not differ (P  0.86).
To determine whether the nigrostriatal fibers protected by
Ad.c-JunDN could be stimulated to release dopamine, we chal-
lenged groups of adenovirus-treated MFB axotomized rats with
amphetamine (2.0 mgkg, s.c.), and analyzed striatal concentrations
of released dopamine as measured by levels of 3,4-dihydroxyphe-
nylacetic acid, the principal metabolite of dopamine in rodents.
Depletion of striatal dopaminergic fibers in Ad.lacZ-treated ani-
mals was reflected by a 63% reduction in 3,4-dihydroxyphenylacetic
acid levels after amphetamine administration in the denervated
striatum (P 0.04 paired t test, Fig. 4F). In contrast, and consistent
with the observed neuroprotection of striatal TH fibers in Ad.c-
JunDN-treated rats, amphetamine-induced dopamine release in
the striatum ipsilateral to the MFB transection was normalized in
Ad.c-JunDN-treated animals (P  0.15 paired t test, Fig. 4F).
Axotomy-Induced Phosphorylation (Ser73) of c-Jun Is Attenuated by
c-JunDN. Transcriptional activation of c-Jun is facilitated by phos-
phorylation by members of the mitogen-activated protein (MAP)
kinase superfamily (reviewed in ref. 31). Specifically, phosphory-
lation of Serine residues 63 and 73 (pSer63 and pSer73) of c-Jun by
JNKSAPK enhances c-Jun transactivation (32–34). Likewise, JNK
activity is positively regulated by the upstream kinase, MAP kinase
kinase 4 (MKK4), which phosphorylates threonine and tyrosine
residues in JNK. To determine whether expression of c-JunDN in
the SNc influenced axotomy-induced changes in activation of c-Jun
by JNKSAPK, we examined changes in phosphorylation of resi-
dues Serine 63 (pSer63) or Serine 73 (pSer73) of c-Jun by using
epitope-specific antibodies. No changes in pSer63 phosphorylation
were detected at any time after axotomy in either adenovirus
treatment group, consistent with previous reports (8). However, the
possibility remains that Ser63 of c-Jun may be a labile site and the
perfusionfixation of tissues may negatively effect the ability to
detect the weak phosphorylation of c-Jun at this residue (35). In
contrast, axotomy induced an increase in phosphorylation of Ser73
in the ipsilateral SNc of Ad.lacZ-treated rats (Fig. 5D). Interest-
ingly, pSer73 was also observed in the ventral tegmental area (VTA)
and medial geniculate nucleus (MGN) adjacent to the SNc (Fig. 5
A and G). Because retrograde labeling from the striatum labeled
only SNc neurons, the VTA and MGN were used as an internal
control for quantification of pSer73 immunoreactivity. Quantifica-
tion revealed that phosphorylation of c-Jun (pSer73) was blocked in
the SNc (Fig. 5 D–F), where c-JunDN was expressed. No differ-
ences in activation of c-Jun were detected in either the VTA (Fig.
5 A–C) or MGN (Fig. 5 G–I) of Ad.lacZ- and Ad.c-JunDN-treated
animals 7 days after axotomy. Consistent with this observation,
induction of endogenous c-Jun protein in the SNc after axotomy
was also impaired only in animals expressing c-JunDN (Fig. 6F,
which is published as supporting information on the PNAS web site,
www.pnas.org). c-JunDN expression also did not appear to effect
the expression pattern of other select immediate early genes in the
SNc after axotomy. As previously reported by others, expression of
JunD (6) is induced, CREB (36) reduced, and expression of FosB
in the SNc is unchanged after axotomy (6). When compared with
tissues from Ad.lacZ-treated animals, axotomy-induced expression
of these three IEG proteins was not affected by expression of
c-JunDN (Fig. 6). To also address the possibility that the observed
impairment of Ser73 phosphorylation of c-Jun by c-JunDN in nigral
neurons was due to an interruption of upstream c-Jun pathway
kinases, we examined for axotomy-induced expression of pMKK4.
By using an antibody specific for phosphorylated (activated) MKK4
(Thr261), an increase in pMKK4 was evident in nigral neurons by 3
days after MFB axotomy, and diminished by 7 days postaxotomy,
similar to what has been previously reported (37). More impor-
tantly, elevated pMKK4 in SNc neurons after axotomy was ob-
served in both Ad.c-JunDN and Ad.lacZ treatment groups (data
not shown). Hence, in this axotomy model, modulation of endog-
enous c-Jun expression rather than interruption of upstream sig-
naling elements of the c-JunJNK pathway likely mediated the
neuroprotective actions of c-JunDN.
Discussion
c-Jun and Axotomy-Induced Neuronal Death. Axotomy of the nigro-
striatal dopamine pathway by mechanical transection of the medial
forebrain bundle evokes the sustained induction of the c-JunJNK
pathway in nigral neurons (6). However the role of c-Jun in neurons
of the CNS after axotomy injury has been controversial (12)
because expression of c-Jun may serve to function either as a
survival response to stress or as a potential mediator of neuronal
demise after injury (15, 38–43). In addition, a role of c-Jun
expression in axonal regrowth after fimbria-fornix transection of
Fig. 4. Degeneration of dopaminergic axon fibers in the striatum is attenuated
by c-JunDN. Immunohistochemical detection of dopamine fibers in the striatum
of adenovirus-treated rats was examined 2 weeks after MFB axotomy. Immuno-
staining for TH in the unlesioned hemisphere of Ad.lacZ and Ad.c-JunDN axoto-
mized rats revealed dense afferent fibrous staining in the striatum (A and C;
respectively). A profound reduction in striatal TH fiber staining in Ad.lacZ was
observed (B), whereas Ad.c-JunDN-treated animals exhibited a marked attenu-
ation of this loss (D). Quantification of striatal densities is shown in E (*, P0.02).
Axotomized striatal afferents in Ad.c-JunDN-treated animals released dopamine
inresponsetoadministrationofamphetamine (2.0mgkg, s.c.),whereasAd.lacZ-
treated animals exhibited a marked deficit in responsiveness (F, P 0.02). Scale
bar 60 m.
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cholinergic neurons (44) and retinal ganglion cells (45) has also
been suggested. In contrast, c-Jun expression has been correlated
with cell death of dopamine neurons after MFB transection (8).
Interestingly, treatment with FK506, which attenuates neuronal loss
in this model, also reduced expression of c-Jun (25). Given the
uncertainty of the role of c-Jun, we directly tested the hypothesis
that expression of c-Jun in dopamine neurons is a key determinant
of whether a neuron will survive axotomy. Our results demonstrate
that expression of c-JunDN is neuroprotective, supporting the
notion that axotomy-induced neuronal death is signaled through a
c-JunJNK dependent pathway.
Neuroprotection by c-Jun Dominant Negative. The question of how
c-JunDN may interfere with neuronal death signals to evoke
neuroprotection in this axotomy model has several possible an-
swers. First, c-JunDN may interfere with stress-activated gene
expression in nigral neurons. In vitro studies have previously shown
that N-terminal deletions of c-Jun (	169 c-Jun) do not impair the
bZIP-mediated binding of c-JunDN to endogenously expressed
IEG proteins, suggesting that overexpression of c-JunDN may
modulate cellular responses by ‘‘quenching’’ resident Fos and Jun
transcriptional activities (46, 47). Therefore, the ability of c-JunDN
to prevent axotomy-induced death of nigral dopamine neurons in
vivo may reflect the ability of c-JunDN to bind IEG proteins and
thereby alter axotomy-induced neuronal gene expression. However,
it is important to note that expression of c-JunDN did not effect
expression patterns of several IEGs, such as JunD, CREB, or FosB,
indicating certain selectivity of c-JunDN action. Second, we have
shown that axotomy-induced phosphorylation of c-Jun (Ser73) in
the SNc was attenuated by expression of c-JunDN. This observation
is likely accountable by active repression of endogenous c-Jun
expression by c-JunDN, as previously described in vitro (48).
Alternatively, c-JunDN may have directly interfered with JNK in
vivo, although absence of the c-Jun delta () domain, amino acids
31–60, has been reported to reduce the affinity of c-JunDN for JNK
(49). Finally, the protracted expression of c-JunDN before the
axotomy may have also altered basal activator protein-1 (AP-1)-
regulated gene expression, and therein modified the subsequent
genetic response of the neurons to injury.
The results of this study support the notion that axotomy-related
c-Jun expression in CNS neurons is associated with neuron death.
This finding, however, is inconsistent with the role proposed for
Fig. 5. MFB axotomy-induced phosphorylation of c-Jun Ser73 is significantly attenuated by Ad.c-JunDN in the SNc. Increased c-Jun-Ser73 was detected in the MGN (A,
B, and C), the SNc (D, E, and F), and VTA (G, H, and I), of Ad.lacZ (A, D, and G), and Ad.c-JunDN (B, E, and H) animals after MFB axotomy. Quantification of Ser73
immunoreactive cells (C, F, and I) in the MGN, SNc, and VTA is shown (P 0.001 ANOVA; **, P 0.01 Newman-Keuls test). (J) Schematic of coronal rat brain section
indicating square area used for quantitative analyses of c-Jun phosphorylation (adapted from Paxinos and Watson, ref. 24). Scale bar 180 m.









c-Jun in medial septal neurons (MSN) after transection of the
fimbria-fornix (44). Whereas SNc neurons degenerate within weeks
after axotomy (14), MSN neurons may survive for an extended
period before dying (10, 11, 30). The disparity in rates of survival
in these two populations of CNS neurons may be related to the
induction of IEG expression in the axotomized neurons. For
instance, whereas axotomy of MSN elicits sustained expression of
c-Jun, these neurons do not display prolonged expression of other
numerous leucine zipper-containing proteins, which are clearly
expressed after MFB axotomy (6). This induction of a variety of
potential activator protein-1 binding partners in SNc neurons after
MFB axotomy may lead to death signals not robustly activated in
MSN neurons (11). Whereas the downstream effects of c-Jun
activation, which mediate axotomy-induced injury, are unknown,
several groups have identified c-Jun in the regulation of several
target genes linked to cell death pathways, including the proapo-
ptotic Bcl-2 member BIM (50, 51), the tumor suppressor p53 (52),
and cyclin D1 (53, 54). The contribution of these and other c-Jun
activated targets in the axotomy-induced death of SNc neurons
remain to be elucidated.
c-Jun and Axonal Degeneration. One important observation of the
present study was that overexpression of c-JunDN significantly
attenuated the loss of afferent striatal dopaminergic fibers. It is
becoming increasingly evident that the synapse can function and
respond to stimuli or stress independent of the neuronal soma, as
exemplified by the demonstration that death-related processes can
occur in synaptosomal preparations and anucleated neurons (55,
56). These findings suggest that autonomous biochemical events
within neurites, separate from the regulation of neural soma, may
retain the machinery for delayed axonal death and thereby offer the
potential for extended survival of axons by inhibition of these
localized events (57).
Whereas the exact mechanism by which c-JunDN delayed neu-
rite degeneration after MFB axotomy is presently unclear, there are
several plausible explanations for this observation. First, because
overexpression of c-JunDN preceded axotomy in the CNS injury
model used in the present study, it could be proposed that the
presence of c-JunDN modified the regulation of c-Jun responsive
target genes before the injury. Alternatively, administration of
Ad.c-JunDN into the axon field, the striatum, may have also
affected the response of the postsynaptic cells to the axotomy of
nigrostriatal dopaminergic fibers. For instance, the survival of
transected Aplysia axons can be significantly prolonged indepen-
dent of de novo protein synthesis (58), or when contact with neurons
is retained (59). The survival of severed dopaminergic axons by
expression of c-JunDN merits further study to elucidate the nature
of this merotrophism (60). Interestingly, several pools of inducible
JNK reside within the cytoplasm and nucleus of neurons (61). In
this context, overexpression of c-JunDN may obstruct the major
available pool of stress-inducible JNK in the axoplasm, and inhibit
JNK phosphorylation of cytoplasmic target after injury (61).
c-Jun as a Therapeutic Target for Neuroprotection. Central to our
understanding of the potential molecular regulation of neuronal
fate after axotomy is the role of proteins that interact with, or are
regulated by, c-Jun. Elucidation of axotomy-induced c-Jun regu-
lated genes may further our understanding of the basic processes
governing neuron fate after axotomy injury. Nevertheless, our
findings suggest that strategies that inhibit the c-JunJNK signaling
cascade, such as pharmacological JNK inhibitors or the application
of c-Jun antisense, may offer the potential of clinical utility for
situations of CNS nerve fiber injury.
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